INSIGHTS ON DRUG DEVELOPMENT
-
Biofluorescent Particle Counters Are Gaining Momentum
The 2025 BioPhorum report highlights challenges and trends in drug filling operations and how they are advancing towards biofluorescent particle counters. Discover an approach that aligns with industry needs.
-
Leveraging Optimized Transient Expression For Material Generation And Early Stage Insight
By using an optimized transient transfection platform, drug developers can accelerate their characterization and early development activities, facilitating continuity for a drug's scale-up.
-
Concept To Market: Scaling And Manufacturing Semi-Solid Topical Drugs
Learn how formulation, processing, and scale‑up choices impact the stability, structure, and performance of semi‑solid topicals while ensuring consistent quality through development.
-
Fast And Efficient Processing Of ELISA Assays
Explore how a streamlined ELISA workflow using automated washing and reading tools enabled accurate detection of hepatitis B markers with no false results.
-
API In Capsule Vs. The Lost Art Of Formulation Development11/5/2025
API-in-capsule offers a fast path for early clinical data, but it can't eliminate the need for full formulation development. Weighing the potential for higher total development time and cost is critical.
-
The Benefits Of Incorporating Lean Methodologies Into Project Management8/20/2024
Delve into the core principles of lean project management and explore how these principles can be integrated with traditional methods to enhance project outcomes.
-
The Top Tech Transfer Risks At Multi-Site CDMOs3/31/2026
Many tech transfer risks are avoidable with a single campus CDMO. With all manufacturing facilities on one site, drug sponsors can overcome obstacles and maintain speed en route to market.
-
Target Product Profiles And Phase 1 Clinical Plans: Laying The Groundwork For Success2/26/2025
By integrating scientific rigor, regulatory foresight, and market awareness into early-stage planning, companies can leverage a robust TPP to optimize decision-making and development.
-
A Scientist's Perspective: Minimizing Hands-On Time In Molecular Assays3/26/2026
Autonomous digital PCR provides absolute quantification in complex matrices. Achieve five-color multiplexing and streamlined data collection without standard curves to accelerate synthetic biology.
DRUG DEVELOPMENT SOLUTIONS
-
Leica M80 Routine Stereo Microscopes
Easily inspect, screen, observe or document. Handle your daily inspection or documentation, work confidently, and stay flexible in times of change. The modular stereo microscopes of the M series from Leica are the right choice for an abundant variety of tasks in life sciences and industrial applications.
The M50, M60, and M80 allow operators to see a large sample overview, work comfortably under the microscope, and capture images of important details easily.
-
Encoded stereo microscopes Leica M165 C - Total recall of your settings
Your goal: high-quality images that allow measurements and can be accurately repeated with minimal effort. The Leica coded stereo microscopes help you to pave the way to correct results.
-
Coded microscopes consistently deliver calibrated and comparable images
-
Reproduce images in moments with the Leica “Store and Recall” function
-
Fully apochromatic corrected zoom optics deliver high quality images
-
Customize the microscope system to your task with the exclusive range of accessories
-
-
Accelerate your gene therapy manufacturing with the Xcellerex™ X-platform – a next-generation single-use bioreactor system designed for viral vector workflows.
-
The commercialization of a combination product can be a complex process that involves obtaining the proper data, choosing a drug delivery system, developing a regulatory strategy and conducting clinical trials—all of which can increase development risks and affect your molecule’s time to market.
-
Partner with a trusted, globally proven CDMO whose world-class, rapidly scalable facilities and unwavering commitment to quality help accelerate patient access to life-saving biologics.